Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypothalamic Obesity Clear all
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jul 22, 2026, 2:02 AM EDT
Withdrawn Not applicable Interventional

Deep Brain Stimulation Effects in Patients With Chronic Refractory Obesity

NCT04453020
View directory record Official record
Conditions
Obesity
Interventions
DBS of the LHA
Device
Lead sponsor
donald whiting
Other
Eligibility
22 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

NCT03479437
View directory record Official record
Conditions
Genetic Forms of Extreme Obesity
Interventions
Not listed
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Functioning of Feeding Centers in Obese Youth

NCT01808846
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
12 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Macronutrient Regulation of Ghrelin and Peptide YY

NCT02464514
View directory record Official record
Conditions
Obesity, Prader Willi Syndrome
Interventions
High carbohydrate meal, High fat meal
Other
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients

NCT00686608
View directory record Official record
Conditions
Obesity
Interventions
glucose, fructose, saline
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Hypothalamic Gliosis on Appetite Regulation and Obesity Risk in Children

NCT04260048
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
9 Years to 11 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Withdrawn Not applicable Interventional

Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )

NCT02441491
View directory record Official record
Conditions
ROHHAD Syndrome
Interventions
Cyclophosphamide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 22 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation Effects on Weight Change and Metabolic Rate

NCT01933113
View directory record Official record
Conditions
Obesity
Interventions
Deep Brain Stimulation of the Lateral Hypothalamic Area
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity

NCT00562796
View directory record Official record
Conditions
Obesity, Growth Hormone
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Not applicable Interventional

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

NCT00688987
View directory record Official record
Conditions
Obesity, Addison's Disease
Interventions
Hydrocortisone, Isocaloric Diet
Drug · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Jul 22, 2026, 2:02 AM EDT
Recruiting No phase listed Observational

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

NCT02602769
View directory record Official record
Conditions
Childhood Obesity, Morbid Obesity
Interventions
Transcriptome profiling
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Boston, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 22, 2026, 2:02 AM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 22, 2026, 2:02 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

NCT01237041
View directory record Official record
Conditions
Obesity, Short Stature, Growth Hormone Deficiency
Interventions
Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 14 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Jul 22, 2026, 2:02 AM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873
View directory record Official record
Conditions
Obesity, Overweight, Craniopharyngioma
Interventions
Exenatide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

NCT06686537
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Estradiol Patches
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of Setmelanotide

NCT06596135
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does What You Eat Affect Your Brain

NCT05626907
View directory record Official record
Conditions
Gliosis, Obesity, Eating
Interventions
Diet modification #1, Diet modification #2, Diet modification #3
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 2:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 2:02 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Reversal of the Reprometabolic Syndrome

NCT07227766
View directory record Official record
Conditions
Obesity & Overweight, Infertility, Female
Interventions
Low-fat diet
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 22, 2026, 2:02 AM EDT